Skip to main content

Table 2 Baseline characteristics of patients from Asia, Central Europe, and Latin America compared with total PRISTINE populationa

From: Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

Characteristic

Patients from Asia, Central Europe, and Latin America (n = 171)

Full PRISTINE population (n = 273)

Age, years

45.3 (12.5)

43.9 (12.7)

Male gender, n (%)

127 (74.3)

190 (69.6)

Ethnicity, n (%)

  

 White

90 (52.6)

174 (63.7)

 Asian

47 (27.5)

64 (23.4)

 Other

34 (19.9)

35 (12.8)

Body weight, kg

85.9 (18.3)

85.1 (18.6)

Body mass index, kg/m2

  

 Male

28.5 (4.8)

28.3 (4.6)

 Female

31.6 (7.6)

29.6 (7.5)

Waist to hip ratio

  

 Male

1.0 (0.1)

1.0 (0.1)

 Female

0.9 (0.1)

0.9 (0.1)

Prior smokers, n (%)

57 (33.7)

109 (40.2)

Psoriasis disease duration, years

16.4 (9.4)

17.3 (10.6)

PASI total score

22.3 (9.6)

21.2 (9.4)

PGA score

3.4 (0.8)

3.4 (0.8)

Affected body surface area, %

37.4 (21.1)

33.0 (20.2)

History of psoriatic arthritis, n (%)

64 (37.4)

84 (30.8)

Duration of psoriatic arthritis, years

7.6 (6.3)

8.2 (8.0)

Secondary diagnosis of diabetes, n (%)

21 (12.3)

26 (9.5)

Secondary diagnosis of hypertension, n (%)

74 (43.3)

97 (35.5)

  1. aData are given as mean (standard deviation) unless otherwise specified
  2. PASI Psoriasis Area and Severity Index, PGA Physician Global Assessment of psoriasis